InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort

PHASE2TerminatedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

June 8, 2020

Primary Completion Date

March 30, 2022

Study Completion Date

March 30, 2022

Conditions
COVID-19Lymphocytopenia
Interventions
DRUG

Interleukin-7

Intramuscular (IM) administration of CYT107 at 3 μg/ kg followed, after 48hrs of observation, by 10 μg/kg twice a week for 2 weeks or

DRUG

Placebo

Intramuscular (IM) placebo (normal saline) at the same frequency

Trial Locations (6)

37000

Chru Tours, Tours

45067

Chr Orleans La Source, Orléans

69003

Hôpital Edouard Herriot, Lyon

69437

hopital Edouard Herriot, Lyon

75014

hopital COCHIN, Paris

87042

University Hospital of Limoges, Limoges

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

University Hospital, Limoges

OTHER

collaborator

Amarex Clinical Research

OTHER

lead

Revimmune

INDUSTRY

NCT04407689 - InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort | Biotech Hunter | Biotech Hunter